Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
10 2019
Historique:
received: 07 03 2019
revised: 25 04 2019
accepted: 10 06 2019
pubmed: 6 8 2019
medline: 17 9 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

To identify preoperative risk factors for disease recurrence, following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), and to create a predictive nomogram. Based on a multicenter database, we identified patients who underwent RNU due to high grade UTUC. Urothelial carcinoma of the bladder or contralateral UTUC was not considered as recurrence. Cox regression model was used to determine the effect of different preoperative variables as predictors of recurrence. Two hundred and forty-five patients were included in the analysis. The 2 and 5 years recurrence rates were 16.3% and 19.2%, respectively. Factors associated with recurrence on univariable analysis were sessile architecture hazard ratio (HR) 3.16 (95% CI, 1.38-7.26, P = 0.006), ≥cT3 disease HR 2.30 (95% CI, 1.12-4.72, P= 0.023), age >65 HR 2.02 (95% CI, 1.00-4.05, P= 0.048), Eastern Cooperative Group > 0 HR 1.98 (95% CI, 1.09-3.57, P= 0.023), hydronephrosis HR 1.93 (95% CI, 1.04-3.57, P= 0.035). Higher hemoglobin levels HR 0.81 (95% CI, 0.69-0.96, P= 0.013) and preoperative estimated glomerular filtration rate ≥ 50 HR 0.48 (95% CI, 0.25-0.92, P = 0.028) were associated with lower probability for recurrence. Multivariable analysis identified sessile architecture as the only independent predictor of recurrence HR 2.52 (95% CI, 1.09-5.86, P= 0.0308). C-index of 0.71 was calculated for a predictive model including all variables in the multivariable analysis, indicating good predictive accuracy. A nomogram predicting 2 and 5 year recurrence free probability was developed accordingly. Based on a multicenter database, we developed a nomogram with good predictive accuracy for recurrence following RNU. This may serve as an aid in decision-making regarding the use of neoadjuvant chemotherapy.

Identifiants

pubmed: 31378586
pii: S1078-1439(19)30238-8
doi: 10.1016/j.urolonc.2019.06.009
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

758-764

Subventions

Organisme : NCI NIH HHS
ID : T32 CA136515
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Yuval Freifeld (Y)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Rashed Ghandour (R)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Nirmish Singla (N)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Solomon Woldu (S)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Timothy Clinton (T)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Rohan Kulangara (R)

University of Texas Southwestern, Medical School, Dallas, TX.

Aditya Bagrodia (A)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Surena F Matin (SF)

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX.

Firas G Petros (FG)

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX.

Jay D Raman (JD)

Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.

Haley Robyak (H)

Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.

Jingsheng Yan (J)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.

Hong Zhu (H)

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX.

Leonid Rapoport (L)

Research Institute of Uronephrology and Human Reproductive Health, I.M Sechenov First Moscow State Medical University, Moscow, Russia.

Yair Lotan (Y)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

Vitaly Margulis (V)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Vitaly.Margulis@utsouthwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH